Open access
Aug 2026
TL1A-DR3 Signaling in Inflammatory Bowel Disease: From Pathogenesis to Therapeutic Targeting.
Current evidence highlights TL1A blockade as a promising dual-pathway therapeutic approach targeting inflammation and fibrotic remodeling, with ongoing studies expected to define its long-term impact on disease modification.
Kozo Tsuruta, Shinichiro Yoshioka, Hidetoshi Takedatsu
· The Kurume Medical Journal · 0 citations